Cefzlan CV Dry Syrup is a potent combination of cefixime and clavulanic acid designed for the effective treatment of bacterial infections in children and adults. This formulation harnesses the antibacterial properties of cefixime, a cephalosporin antibiotic, which targets a wide range of gram-positive and gram-negative bacteria. Clavulanic acid is included to inhibit beta-lactamase enzymes produced by resistant bacteria, thereby enhancing the efficacy of cefixime and broadening its spectrum of activity.
The syrup is particularly indicated for conditions such as respiratory tract infections, otitis media, urinary tract infections, and skin infections caused by susceptible bacteria. Its pleasant taste makes it more palatable for pediatric patients, ensuring better compliance with the prescribed treatment regimen.
Cefzlan CV Dry Syrup is administered orally, and the dosage is typically determined by the physician based on the patient's age, weight, and severity of the infection. It is crucial to complete the full course of the antibiotic even if symptoms improve, to prevent the development of antibiotic resistance.
While Cefzlan CV is generally well-tolerated, some patients may experience side effects. Common adverse reactions include gastrointestinal disturbances such as diarrhea, nausea, and vomiting. Allergic reactions, though rare, may occur, presenting as skin rash, itching, or swelling. Patients should be advised to seek medical attention if they experience severe or persistent side effects.